CHROMADEX CORP (CDXC) Stock Fundamental Analysis
NASDAQ:CDXC - Nasdaq - US1710774076 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to CDXC. CDXC was compared to 55 industry peers in the Life Sciences Tools & Services industry. While CDXC has a great health rating, its profitability is only average at the moment. CDXC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CDXC was profitable.
CDXC had a positive operating cash flow in the past year.
In the past 5 years CDXC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CDXC reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.52%, CDXC belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
CDXC has a better Return On Equity (18.55%) than 90.91% of its industry peers.
CDXC has a better Return On Invested Capital (12.13%) than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROIC | 12.13% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDXC has a Profit Margin of 8.58%. This is in the better half of the industry: CDXC outperforms 74.55% of its industry peers.
Looking at the Operating Margin, with a value of 7.76%, CDXC is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
With an excellent Gross Margin value of 61.84%, CDXC belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
In the last couple of years the Gross Margin of CDXC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CDXC is creating some value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
CDXC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CDXC has an improved debt to assets ratio.
2.2 Solvency
CDXC has an Altman-Z score of 15.46. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.46, CDXC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
CDXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.46 |
ROIC/WACC1.11
WACC10.97%
2.3 Liquidity
A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
The Current ratio of CDXC (3.57) is comparable to the rest of the industry.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
The Quick ratio of CDXC (3.06) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.86% over the past year.
Looking at the last year, CDXC shows a quite strong growth in Revenue. The Revenue has grown by 19.17% in the last year.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
3.2 Future
Based on estimates for the next years, CDXC will show a very strong growth in Earnings Per Share. The EPS will grow by 43.55% on average per year.
Based on estimates for the next years, CDXC will show a quite strong growth in Revenue. The Revenue will grow by 19.24% on average per year.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 78.70, which means the current valuation is very expensive for CDXC.
Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.31. CDXC is valued rather expensively when compared to this.
CDXC is valuated quite expensively with a Price/Forward Earnings ratio of 66.13.
CDXC's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.13. CDXC is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CDXC indicates a somewhat cheap valuation: CDXC is cheaper than 61.82% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CDXC is valued a bit cheaper than the industry average as 65.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.22 | ||
| EV/EBITDA | 66.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CDXC may justify a higher PE ratio.
A more expensive valuation may be justified as CDXC's earnings are expected to grow with 43.55% in the coming years.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%
5. Dividend
5.1 Amount
No dividends for CDXC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.87
-0.07 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change10.7%
Ins Owners0.01%
Ins Owner Change0.07%
Market Cap611.89M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 | ||
| P/S | 6.14 | ||
| P/FCF | 51.22 | ||
| P/OCF | 50.53 | ||
| P/B | 13.27 | ||
| P/tB | 13.38 | ||
| EV/EBITDA | 66.44 |
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROCE | 15.35% | ||
| ROIC | 12.13% | ||
| ROICexc | 104.84% | ||
| ROICexgc | 111.73% | ||
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% | ||
| FCFM | 11.99% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 20.02% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 7726 | ||
| Cash Conversion | 141.79% | ||
| Profit Quality | 139.72% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | 15.46 |
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A